Paratek Pharmaceuticals, Army Partner for Omadacycline Biodefense Studies
Paratek Pharmaceuticals has partnered with the U.S. Army to conduct research on the efficiency of omadacycline treatments against pathogenic agents under a cooperative research-and-development agreement. The studies will work to determine if omadacycline can help treat biodefense pathogens such as Yersinia Pestis and Bacillus Anthracis, Paratek said Tuesday. The company will provide omadacycline and technical expertise in support of the U.S. Army Medical Research Institute of […] More
